Better glycemic control seen with basal insulin plus lixisenatide

09/24/2013 | Healio

Diabetes patients who used lixisenatide as an add-on to basal insulin had lower A1C, body weight and self-measured blood glucose profiles than those in the placebo arm, researchers reported at the European Association for the Study of Diabetes meeting. Patients with baseline fasting plasma glucose of less than 6.7 mmol/L showed greater placebo-adjusted improvements compared with those who had higher fasting glucose levels, researchers added.

View Full Article in:

Healio

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX